SecBot SecBot
SECBOTREPLAY Home › Report › ANIK

ANIK · Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP…

Anika Therapeutics, Inc. · 8-K filed Jul 29, 2026 at 07:20 ET

At the news

BULLISHIMPACT 8/10

8-K filed Jul 29, 2026 at 07:20 ET

Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP EPS of $0.24 (vs $0.03 consensus) and revenue of $32.6M (vs $29.2M consensus), driven by record Commercial Channel revenue of $13.9M (+17% YoY) and gross margin expansion to 65%. The company raised full-year 2026 guidance across all metrics, most notably lifting adjusted EBITDA margin guidance from 5%-10% to 13%-17%, signaling a structural profitability inflection. The bullish read is tempered by the removal of Hyalofast revenue from 2027 guidance due to FDA timing uncertainty, but the magnitude of the beat and guidance raise dominates the narrative for a $202M market cap stock.

  • Q2 2026 revenue $32.6M, up 16% YoY vs $28.2M, beating $29.2M consensus
  • GAAP diluted EPS $0.24 vs consensus $0.03 (700% beat); adjusted diluted EPS $0.42
  • Gross margin expanded to 65% from 51% in Q2 2025, driven by volume and mix
  • Adjusted EBITDA $7.1M (22% margin), highest since 2020, vs -$0.2M in Q2 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access